Investor Relations
AMS at a Glance
Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.
Our primary focus is to create quality outcomes for our:
- Customers
- Patients
- Shareholders
Financial Calendar
Full Year Period End
31 December 2021Half Year Period End
30 June 2021Final Dividend Payment
18 June 2021Annual General Meeting
June 2021Preliminary Results Announcement
17 March 2021Financial Reports
2020 Annual Report
April 2021Notice of AGM
April 20212020 Interim Report
September 20202019 Annual Report
May 2020Notice of AGM
May 20202019 Interim Report
September 20192018 Annual Report
April 20192018 Interim Report
September 20182017 Annual Report
April 20182017 Interim Report
September 20172016 Annual Report
April 20172016 Interim Report
September 20162015 Annual Report
April 20162015 Interim Report
October 20152014 Annual Report
April 20152014 Interim Report
September 20142013 Annual Report
April 2014News
Advanced Medical Solutions Group plc today announces that it has acquired Raleigh Adhesive Coatings Limited (“Raleigh”), an independent woundcare and bio-diagnostics... Read More
Advanced Medical Solutions Group plc today announces it has acquired French company Biomatlante SA (“Biomatlante”), a well-established international developer and manufacturer... Read More
Latest Highlights
Having created a designated COVID-19 working group, prioritised safe working practices and complied with government measures on social distancing, all AMS sites have remained in operation throughout the pandemic and the Group has been able to service the demand of its healthcare partners throughout 2020 while maintaining its robust balance sheet.
COVID-19 restrictions disrupted our global markets in 2020, with a resulting slowdown in surgical and wound treatment volumes. In addition, reduced access to hospitals has significantly restricted business development activities during the year. In line with consensus market forecasts, Group sales and profitability were heavily impacted. Group revenue declined to £86.8 million (2019: £102.4 million) and the resulting adverse operating leverage led to adjusted profit before tax reducing to £13.4 million (2019: £26.6 million) and adjusted diluted earnings per share reducing to 5.4p (2019: 9.8p).
Investment in R&D increased to £7.9 million (2019: £6.5 million) as progress continued on all key projects across the Group. We received approval and launched LiquiBand® Rapid™ and successfully completed LiquiBand® XL clinical trials, which keeps us on track for approval and launch towards the end of 2021. Progress on the US clinical trial for LiquiBandFix8® progressed well with a filing expected in 2022. Patient enrolment for the first human clinical study of Seal-G® and Seal-G® MIST began in February and CE mark extensions for the product are expected imminently giving AMS access to a new $1 billion addressable market with a differentiated product to fulfil a significant unmet need.
The acquisition of Raleigh Adhesive Coatings Limited in November 2020 for £22 million provides a strong strategic fit with commercial synergies and new commercial opportunities.
Given the Group’s strong net cash position and reflecting the Board’s confidence in the future, an increased full year dividend is proposed. In line with best practice, AMS repaid the £0.4 million of UK Government furlough support received during the year.
As COVID-19 vaccine programmes roll out in key markets, we await the reduction in infection rates and a gradual return to normalised levels of elective surgery across all of our markets.